Johnson & Johnson (NYSE: JNJ) recently reported its Q3 results, with revenues and earnings exceeding our estimates.
Leerink Partners analyst David Risinger has maintained their bullish stance on ANAB stock, giving a Buy rating yesterday. David Risinger has ...
The lawsuit focuses on scientific work that helped clear the path for creating mRNA vaccines to fight the COVID-19 pandemic.